The proteasome inhibitor bortezomib is registered in the US for use in multiple myeloma, but its antitumor activity has not been tested in patients with indolent or MANTLE-CELL LYMPHOMA (MCL).

A patient with relapsed/refractory non-Hodgkin lymphoma received the first dose of a two-step radiotherapy using the ...

The outcome of patients with mantle cell lymphoma (MCL) has largely improved over the past ... Patients with so-called leukemic non-nodal (indolent) MCL 6 were excluded. This open-label, randomized, ...

METHODS: Patients aged ≥65 years with previously untreated mantle cell lymphoma received acalabrutinib (100 mg twice daily) or placebo (until disease progression or unacceptable toxicity), plus 6 ...

Martin Dreyling, investigator in the trial, said, "This approval provides a new first-line treatment option for patients in the EU with mantle cell lymphoma, an aggressive lymphoma with a dismal ...

and 1 with T-cell histiocyte-rich B-cell lymphoma; 6 patients had follicular lymphoma, and 3 had mantle-cell lymphoma. Patients had been heavily pretreated with a median of 7 previous therapies ...

AstraZeneca (AZ) has announced that its Bruton’s tyrosine kinase (BTK) inhibitor Calquence (acalabrutinib) has been approved by the European Commission (EC) as part of a combination treatment for ...

AstraZeneca’s Calquence (acalabrutinib) in combination with bendamustine and rituximab has been approved in the European Union (EU) for the treatment of adult patients with previously untreated mantle ...

Six patients had follicular lymphoma, and three had mantle cell lymphoma. Patients had been heavily pretreated, with a median of seven previous therapies, and all but one had been treated with a ...

including in the disease subsets of large B-cell lymphoma (LBCL) and mantle cell lymphoma (MCL). While the common treatment-related toxicities of cytokine release syndrome (CRS) and immune ...